Active, not recruitingPhase 3NCT06151197
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
Studying Ledderhose disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Endo Pharmaceuticals
- Principal Investigator
- Louis OrtegaEndo Pharmaceuticals
- Intervention
- EN3835(biological)
- Enrollment
- 418 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Endo Site 42, Mesa, Arizona, United States
- Endo Site 64, Scottsdale, Arizona, United States
- Endo Site 11, Tucson, Arizona, United States
- Endo Site 49, Castro Valley, California, United States
- Endo Site 39, Cerritos, California, United States
- Endo Site 31, Corona, California, United States
- Endo Clinical Site 2, Encinitas, California, United States
- Endo Site 8, Fresno, California, United States
- Endo Site 28, Lancaster, California, United States
- Endo Site 9, Los Angeles, California, United States
- Endo Site 53, Los Angeles, California, United States
- Endo Site 50, San Francisco, California, United States
- Endo Site 29, Sherman Oaks, California, United States
- Endo Site 30, Tarzana, California, United States
- Endo Site 61, Torrance, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06151197 on ClinicalTrials.govOther trials for Ledderhose disease
Additional recruiting or active studies for the same condition.